Scientific Industries (SCND) reported Q3 2025 results, including revenue of $1.404 million, a 45.5% gross margin, and net income of $3.994 million ($0.34 EPS). They hold $8.3 million in cash, equivalents, and investments (Sep 30, 2025). The Genie division sale boosted results. VIVID sales rose 27% YoY, Torbal division sales increased 15% YTD. An AI enhancement was launched for the VIVID WORKSTATION, and a second generation VIVID-ONE is scheduled for Q1 CY26.
“`html
Scientific Industries (OTCQB: SCND) disclosed its third-quarter 2025 performance and unveiled an artificial intelligence enhancement for its VIVID WORKSTATION on November 20, 2025.
Key Q3 indicators: revenues reached $1.404 million, boasting a gross margin of 45.5%, yielding a net income of $3.994 million, and an Earnings Per Share (EPS) of $0.34. The company declared holdings of $8.3 million in cash, cash equivalents, and investments as of September 30, 2025. The completion of the Genie division sale on August 7, 2025, generated a notable gain that significantly influenced the overall results. Noteworthy product achievements encompassed a 27% year-over-year surge in VIVID sales, a 15% Year-to-Date (YTD) increase in Torbal division sales, and enhancements to the DOTS platform.
Scientific Industries (OTCQB: SCND) ha riportato i risultati del terzo trimestre 2025 e ha lanciato una funzione AI per la sua VIVID WORKSTATION il 20 novembre 2025.
Principali dati del Q3: ricavi 1,404 milioni di dollari, margine lordo 45,5%, utile netto 3,994 milioni di dollari e EPS 0,34 dollari. L’azienda ha riportato 8,3 milioni di dollari in cassa, equivalenti di cassa e investimenti al 30 settembre 2025. La direzione ha completato la vendita della divisione Genie l’8 agosto 2025, registrando un guadagno che ha avuto un effetto sostanziale sui risultati. Tra i punti salienti del prodotto, un aumento delle vendite VIVID del 27% su base annua, vendite della divisione Torbal in aumento del 15% YTD, e miglioramenti della piattaforma DOTS.
Scientific Industries (OTCQB: SCND) informó los resultados del tercer trimestre de 2025 y lanzó una función de IA para su VIVID WORKSTATION el 20 de noviembre de 2025.
Datos clave del Q3: recibos 1,404 millones de dólares, margen bruto 45,5%, ingreso neto 3,994 millones y EPS 0,34. La compañía reportó 8,3 millones de dólares en efectivo, equivalentes de efectivo e inversiones al 30 de septiembre de 2025. La dirección completó la venta de la división Genie el 7 de agosto de 2025, registrando una ganancia que afectó de manera sustancial los resultados. Los aspectos destacados del producto incluyen un aumento de ventas VIVID del 27% interanual, las ventas de la división Torbal subieron 15% en lo que va del año, y mejoras de la plataforma DOTS.
Scientific Industries (OTCQB: SCND)가 2025년 3분기 실적을 발표했고 2025년 11월 20일 VIVID WORKSTATION용 AI 기능을 출시했습니다.
3분기 핵심 수치: 매출 1.404백만 달러, 총 이익률 45.5%, 순이익 3.994백만 달러 및 주당순이익(EPS) 0.34달러입니다. 회사는 2025년 9월 30일 기준으로 현금 및 현금등가물 및 투자자산 830만 달러를 보고했습니다. 경영진은 2025년 8월 7일 Genie 부문 매각을 완료했으며, 이는 결과에 실질적인 영향을 미친다고 보고되었습니다. 제품 하이라이트로는 VIVID 매출이 전년 대비 27% 증가, Torbal 부문 매출이 연초 대비 15% 증가, 그리고 DOTS 플랫폼 개선이 있습니다.
Scientific Industries (OTCQB: SCND) a publié les résultats du troisième trimestre 2025 et a lancé une fonction IA pour son VIVID WORKSTATION le 20 novembre 2025.
Chiffres clés du T3 : revenus 1,404 M$, marge brute 45,5%, résultat net 3,994 M$ et EPS 0,34$. L’entreprise a déclaré 8,3 M$ en liquidités, équivalents de liquidités et investissements au 30 septembre 2025. L’équipe dirigeante a finalisé la vente de la division Genie le 7 août 2025, enregistrant une plus-value qui a eu un effet significatif sur les résultats. Les points forts produits comprennent une hausse des ventes VIVID de 27% sur une base annuelle, les ventes de la division Torbal en hausse de 15% YTD, et des améliorations de la plateforme DOTS.
Scientific Industries (OTCQB: SCND) veröffentlichte die Ergebnisse des dritten Quartals 2025 und brachte am 20. November 2025 eine KI-Funktion für VIVID WORKSTATION auf den Markt.
Wichtige Q3-Zahlen: Umsatz 1,404 Mio. USD, Bruttomarge 45,5%, Nettoeinkommen 3,994 Mio. USD und EPS 0,34 USD. Das Unternehmen meldete 8,3 Mio. USD an Bargeld, liquiden Mitteln und Investitionen per 30. September 2025. Das Management schloss am 7. August 2025 den Verkauf der Genie-Sparte ab, was eine berichtete Gewinn ausweist, der die Ergebnisse wesentlich beeinflusste. Produkt-Highlights umfassen eine 27%-ige YoY-VIVID-Umsatzsteigerung, Torbal-Sparte Verkäufe um 15% YTD und Verbesserungen der DOTS-Plattform.
Scientific Industries (OTCQB: SCND) أصدرت نتائج الربع الثالث 2025 وأطلقت ميزة ذكاء اصطناعي لـ VIVID WORKSTATION في 20 نوفمبر 2025.
أهم أرقام الربع الثالث: إيرادات 1.404 مليون دولار، هامش إجمالي 45.5%، صافي الدخل 3.994 مليون دولار و EPS 0.34 دولار. أبلغت الشركة عن 8.3 مليون دولار من النقد وما يعادله من النقد واستثمارات حتى 30 سبتمبر 2025. أكمل الإدارة بيع قسم Genie في 7 أغسطس 2025، مسجلاً ربحاً أثر بشكل جوهري على النتائج. تشمل أبرز ملامح المنتج زيادة مبيعات VIVID بنسبة 27% على أساس سنوي، وارتفاع مبيعات قسم Torbal بنسبة 15% حتى تاريخه خلال السنة، وتحسينات منصة DOTS.
Positive
VIVID sales +27% YoY
Torbal division sales +15% YTD
Q3 net income $3.994M
Q3 EPS $0.34
Cash and investments $8.3M as of Sep 30, 2025
Gain on Genie sale $5,263,400
Negative
Gross margin declined to 45.5% in Q3 from 51.0% prior year
Nine-month revenues decreased 2.5% to $3.427M
Bioprocessing revenue down $141,700 for the quarter
Loss from continuing operations $5.4347M for nine months
Customer purchase delays due to tariffs and reduced government funding
11/19/2025 – 08:07 PM
TORBAL DIVISION SALES UP 15% YTD LAUNCH OF VIVID’S FIRST AI-POWERED FEATURE SECOND GENERATION VIVID-ONE LAUNCH SCHEDULED FOR Q1 CY26
Investor Call to be held Thursday, November 20th at 11:00 a.m. Eastern Time
BOHEMIA, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) — Scientific Industries, Inc. (OTCQB: SCND), a leading developer of digitally simplified bioprocessing solutions and vision-based pill counters, today reported financial results for the three and nine months ended September 30, 2025, and announced the launch of a new AI-enabled feature for its VIVID WORKSTATION.
Business Highlights:
Launched an innovative prescription label documentation and verification feature for the VIVID WORKSTATION, harnessing AI technology
Achieved a 27% year-over-year sales increase for VIVID products
DOTS MPS Platform augmented with single use nanoparticles for baffled flasks.
2025 Third Quarter Financial Overview:
Net revenues totaled $1.4 million versus $1.3 million in the prior year period
Genie Division sold on August 7, 2025
Gross profit was $0.6 million, compared to $0.7 million in the prior year period
Gross margin was 45.5%, compared to 51.0% in the prior year period
Cash, cash equivalents and investments were $8.3 million as of September 30, 2025
Scientific Industries’ AI Integration Drives Q3 Earnings, VIVID Sales Surge; Focus Shifts to High-Growth Segments.
Scientific Industries (SCND) is making strategic moves, shedding underperforming assets and doubling down on AI-driven solutions to boost its bottom line. The company’s Q3 2025 results released Wednesday, showcase this strategy in action
Helena Santos, Chief Executive Officer of Scientific Industries, stated: “The divestiture of our Genie brand portfolio has sharpened our focus on our high-growth segments, including our pill counting business. With the introduction of AI-driven capabilities in the VIVID WORKSTATION, we are redefining innovation in pharmacy automation. This upgrade not only strengthens compliance and accountability but also delivers significant cost efficiencies for our customers. Our unwavering commitment to continuous improvement—across hardware, firmware, and software—ensures that VIVID pill counters remain at the forefront of automated pill counting solutions.”
“Our relentless focus on innovation – spanning hardware, firmware, and software—keeps VIVID pill counters at the forefront of automated pill counting solutions. This commitment not only drives future revenues, but also builds a powerful and enduring platform of value for our customers,” concluded Ms. Santos.
One of the key highlights from the quarter is the impressive 27% year-over-year sales increase for VIVID products, which Santos attributes to ongoing innovation across hardware, firmware, and software, particularly in automated pill counting solutions. The integration of AI into the VIVID WORKSTATION through a new prescription label documentation and verification feature stands as a key strategic move, poised to enhance compliance, accountability, and cost-effectiveness for pharmacy clients, particularly the productivity in high-volume pharmacies that is being addressed by VIVID’s high throughput capabilities.
John Moore, Chairman said, “Scientific Bioprocessing continues to innovate with the introduction of the world’s first dissolved oxygen sensor designed for baffled flasks. Nine out of ten pilot testers were surprised to discover that their cultures were severely oxygen-limited, meaning they were not producing their Gene of Interest (GOI) as expected. These insights have led to major new customer wins, seamless workflow integrations, and repeat orders. Breakthrough findings like these—helping scientists improve the reproducibility of their experiments—are emerging with each new component added to the DOTS platform. Customers are already looking forward to the pilot results of our new pH sensor, expected in the first quarter of 2026. In the meantime, customer budgets have been affected by tariffs and reduced government funding for scientific research. We have subsequently experienced delays in customer purchases. Despite these challenges, we remain optimistic about the fourth quarter and 2026 and are excited about the future.”
Analyzing the Financials: While revenue for the quarter increased to $1.404 million from $1.334 million in the prior year, the nine-month figures reveal a slight decrease of 2.5%, reflecting overall softness in the bioprocessing market. The sale of the Genie division for $5.263 million significantly boosted net income, resulting in earnings per share of $0.34 for the quarter compared to a loss of $(0.11) in the same period last year.
However, it’s crucial to note that the gross margin contracted to 45.5% from 51.0% due to increased material costs linked to tariffs on Torbal OEM products and pressured margins in the Bioprocessing segment. Additionally, customer purchase delays due to tariffs and reduced government funding highlight the external headwinds Scientific Industries faces.
2025 Third Quarter and Nine-Month Financial Review
Net revenues for the three months ended September 30, 2025, increased $69,600, or 52.2% to $1,404,000 from $1,334,400 for the three months ended September 30, 2024, primarily due to an increase in revenues from the Torbal Division of the Benchtop Laboratory Equipment Operations. Driven by growing demand for VIVID products. Bioprocessing Systems Operations revenues reflected a $141,700 decrease for the quarter due to overall softness in the market and requirements for products not yet available by the Company.
Net revenues for the nine months ended September 30, 2025, decreased $87,500, or (2.5%) to $3,427,100 from $3,514,600 for the nine months ended September 30, 2024, primarily due to decreased Bioprocessing Systems Operations revenues, reflecting an overall softness in the market. The decrease was partially offset by increased revenues from the Torbal Division, with total revenues increased $356,700, or 15% to $2,737,300 for the nine months ended September 30, 2025 compared to $2,380,600 in the prior year period.
The gross profit margin for the three and nine months ended September 30, 2025 was 45.5% and 39.8%, compared to 51.0% and 44.1%, respectively, for the prior year periods, primarily due to the sale of the Genie Division on August 7, 2025. Additionally, increases in material costs due to tariffs for Torbal OEM products, and lower gross margins for Bioprocessing products due to fixed costs on lower sales.
Operating expenses decreased $84,800 and $439,600, to $2,160,900 and $6,797,700, respectively in the three-month and nine-month periods ended September 30, 2025, compared to $2,245,700 and $7,237,300, respectively in the same period in 2024, primarily as a result of decreased expenses resulting from reduced costs by the Bioprocessing Systems Operations.
The Company reflected Total Other Income, Net of $5,526,900 and $5,582,300 for the three and nine months ended September 30, 2025, respectively compared to $78,500 and $169,000, respectively, due to a gain on sale of $5,263,400 from the Genie Division sale on August 7, 2025 to Ohaus Corporation’s affiliate, Troemner, LLC.
As a result, the Company posted net income of $3,994,400, and $692,200 or $0.34 and $0.06 earnings per share for the three and nine month periods ended September 30, 2025, respectively, compared to net losses of $1,180,100 and $4,515,400 or $(0.11) and $(0.43) loss per share for the three and nine month periods ended September 30, 2024, respectively.
Conference Call Details
Scientific Industries will conduct a conference call to discuss financial results for the third quarter of 2025 on Thursday, November 20, 2025, at 11:00 A.M. ET. Interested parties can access the conference call by dialing (844) 481-2706 or (412) 317-0662 (international). A webcast of the call will be available on the Company’s Investor Relations page at https://www.scientificindustries.com/investor-relations/ or at https://app.webinar.net/85AGrAdVN1d.
A replay of the call will be available through November 27, 2025, at (855) 669-9658 or (412) 317-0088 (international), replay access code: 4098504, or for 30 days at https://www.scientificindustries.com/investor-relations/.
About Scientific Industries, Inc.
Scientific Industries (OTCQB: SCND) designs, manufactures, and markets bioprocessing systems under the product name DOTS, and vision-based pill counters under the VIVID brand in addition to weighing instruments. Scientific Industries’ products are generally used in laboratories of universities, hospitals, pharmaceutical companies, and pharmacies. To learn more visit www.scientificbio.com, www.torbalscales.com, and www.pillcounters.com.
Safe Harbor Statement
Statements made in this press release that relate to future events, performance or financial results of the Company are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. The Company undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in the Company’s Securities and Exchange Commission reports, including our annual report on Form 10-K.
—FINANCIAL TABLES FOLLOW—
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
30-Sep-25
31-Dec-24
ASSETS
(Unaudited
)
Cash and Cash Equivalents
$
1,162,600
$
587,900
Investment Securities
7,131,100
1,985,000
Other Current Assets
3,595,000
5,714,800
Intangibles Assets and Goodwill
564,600
861,300
Other Long Term Assets
2,104,100
2,411,800
Total Assets
$
14,557,400
<td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/13198.html
Jan, a seasoned journalist, specializes in major corporations' stock industry and the IT tech internet field. With years of experience, she's known for dissecting global tech giants' stock moves, analyzing financial impacts and industry trends. Jan excels at simplifying complex data and tech concepts, and her work appears in renowned financial and tech publications.
